| [1] |
吕毅，张谞丰．肝细胞肝癌的多学科协作组概念及其实践[J/CD]．中华肝脏外科手术学电子杂志，2013，2(1):1-3.
|
| [2] |
Yeung OW, Lo CM, Ling CC, et al. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma[J]. J Hepatol, 2015, 62(3):607-616.
|
| [3] |
Zhao HQ, Li WM, Lu ZQ, et al. Roles of Tregs in development of hepatocellular carcinoma: a meta-analysis[J]. World J Gastroenterol, 2014, 20(24):7971-7978.
|
| [4] |
McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy[J]. Cancer Med, 2013, 2(5):662-673.
|
| [5] |
Carulli L, Anzivino C. Telomere and telomerase in chronic liver disease and hepatocarcinoma[J]. World J Gastroenterol, 2014, 20(20):6287-6292.
|
| [6] |
Mizukoshi E, Nakagawa H, Kitahara M, et al. Immunological features of T cells induced by human telomerase reverse transcriptase-derived peptides in patients with hepatocellular carcinoma[J]. Cancer lett, 2015, 364(2):98-105.
|
| [7] |
Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy[J]. Science, 2015, 348(6230):69-74.
|
| [8] |
Zhong JH, Ma L, Wu LC, et al. Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review[J]. Int J Clin Pract, 2012, 66(1):21-27.
|
| [9] |
Pan K, Li YQ, Wang W, et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients[J]. Ann Surg Oncol, 2013, 20(13):4305-4311.
|
| [10] |
Li X, Dai D, Song X, et al. A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2014, 38(5):583-591.
|
| [11] |
Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J]. Gastroenterology, 2015, 148(7):1383-1391.
|
| [12] |
Erös de Bethlenfalva-Hora C, Mertens JC, Piguet AC, et al. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma[J]. Clin Sci, 2014, 126(3):243-252.
|
| [13] |
Gehring AJ, Xue SA, Ho ZZ, et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines[J]. J Hepatol, 2011, 55(1):103-110.
|
| [14] |
Gao H, Li K, Tu H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma[J]. Clin Cancer Res, 2014, 20(24):6418-6428.
|
| [15] |
Cany J, Tran L, Gauttier V, et al. Immunotherapy of hepatocellular carcinoma: is there a place for regulatory T-lymphocyte depletion?[J]. Immunotherapy, 2011, 3(4 Suppl):32-34.
|
| [16] |
Lee D, Chung YH, Kim JA, et al. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma[J]. Cancer, 2013, 119(12):2239-2246.
|
| [17] |
Wang L, Jia D, Duan F, et al. Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo[J]. Biochem Biophys Res Commun, 2012, 422(4):687-692.
|
| [18] |
Duffy A, Kerkar SP, Kleiner DE, et al. Paired tumor biopsy analysis and safety data from a pilot study evaluating Tremelimumab-a monoclonal antibody against CTLA-4 in combination with ablative therapy in patients with hepatocellular carcinoma (HCC)[J]. J Immunother Cancer, 2014, 2 Suppl 3:P98.
|
| [19] |
El Ansary M, Mogawer S, Elhamid SA, et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC[J]. J Cancer Res Clin Oncol, 2013, 139(1):39-48.
|
| [20] |
Lee WC, Wang HC, Hung CF, et al. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial[J]. J Immunother, 2005, 28(5):496-504.
|
| [21] |
Tada F, Abe M, Hirooka M, et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma[J]. Int J Oncol, 2012, 41(5):1601-1609.
|